A randomized phase II trial of tipifarnib (R115777, ZARNESTRA, NSC 702818, IND 58,359) in combination with oral etoposide (VP-16) in elderly adults with newly diagnosed, previously untreated acute myelogenous leukaemia

Trial Profile

A randomized phase II trial of tipifarnib (R115777, ZARNESTRA, NSC 702818, IND 58,359) in combination with oral etoposide (VP-16) in elderly adults with newly diagnosed, previously untreated acute myelogenous leukaemia

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2012

At a glance

  • Drugs Etoposide (Primary) ; Tipifarnib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Planned end date changed from 1 Jan 2008 to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 27 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top